By Colin Kellaher
A Food and Drug Administration decision is due this week on a proposed drug from Vanda Pharmaceuticals to treat gastroparesis, a condition that affects the stomach muscles and prevents proper stomach emptying.
The FDA in December 2023 accepted Vanda's application seeking approval of tradipitant for the treatment of symptoms of the digestive condition, and the agency set a target action date of Sept. 18.
Vanda has previously said that an FDA green light would make tradipitant the first novel drug approved by the agency in more than four decades for gastroparesis, but in its second-quarter financial report in late July, Vanda disclosed that the FDA had provided a preliminary notice that deficiencies were precluding the discussion of labeling.
Vanda in April 2012 inked a license agreement with Eli Lilly to develop and commercialize tradipitant for all human indications. Eli Lilly is due a $10 million milestone for the first U.S. approval for tradipitant.
Vanda earlier this year reported positive results from a second Phase 3 study of tradipitant for the treatment of motion sickness and said it planned to file for FDA approval by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 18, 2024 06:43 ET (10:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。